The hemostatic disorders biotechnology company Hemab Therapeutics (COAG.US) applies for listing in the United States with plans to raise up to 100 million US dollars.

Biotechnology company Hemab Therapeutics, dedicated to developing treatments for blood clotting disorders, submitted an application to the US Securities and Exchange Commission (SEC) last Friday, planning to raise up to $100 million in funding through an initial public offering (IPO). Hemab Therapeutics is a clinical-stage biotechnology company focused on developing antibody therapies for the treatment of genetic bleeding and clotting disorders. Its lead candidate drug, sutacimig (HMB-001), has completed Phase II clinical trials and is ready to start Phase III trials for platelet dysfunction and Phase II trials for factor VII deficiency; while HMB-002 is currently in Phase I/II trials for vascular hemophilia. The company is dedicated to developing prophylactic subcutaneous injection therapies for rare diseases with limited treatment options and is also advancing preclinical candidate drugs for other clotting-related disorders. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company plans to list on Nasdaq with the stock symbol "COAG". Hemab Therapeutics submitted the application secretly on February 27, 2026. Goldman Sachs, J.P. Morgan, and Evercore ISI are the joint underwriters for this transaction.